CHRISTOPHER BERNADAS: Open Payments
NPI 1649632050 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$787 in 56 payments from 9 companies in 2025. Trend: 2023 $1,218 · 2024 $876 · 2025 $787
Food & beverage: $787
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 32 | $341 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $198 |
| Janssen Pharmaceuticals, Inc | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Alpha Cognition USA, Inc. | 1 | $14 |
Products named: NUPLAZID, CAPLYTA, INVEGA SUSTENNA, FANAPT, REXULTI, COBENFY, ARISTADA, Zunveyl.
Industry payments across LA — which companies pay providers there.
